My watch list
my.bionity.com  
Login  

Denosumab

Nature Reviews Drug Discovery 9, 591 (2010). doi:10.1038/nrd3244

Authors: René Rizzoli, Uma Yasothan & Peter Kirkpatrick

In May 2010, denosumab (Prolia; Amgen) was granted marketing authorization by the European Commission for the treatment of postmenopausal women with osteoporosis who are at increased risk of fracture, and for the treatment of bone loss associated with hormone ablation therapy in men with prostate

Authors:   René Rizzoli; Uma Yasothan; Peter Kirkpatrick
Journal:   Nature Reviews Drug Discovery
DOI:   10.1038/nrd3244

Watchlist

This is where you can add this publication to your personal favourites.

Additional Information

More about Nature Publishing Group
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE